RMDN1

Across TCGA pan-cancer cohorts, RMDN1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RMDN1 data layer compared with 21 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RMDN1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RMDN1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, PDAC, and HNSC are the cancer types where RMDN1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	II,III,IV	0.928	0.105	.006	26	view →
PDAC	OS	Median	IV	0.381	0.951	.006	15	view →
HNSC	DFS	Median	IV	0.328	0.889	.014	6	view →
LUAD	DFS	Quartile	II,III,IV	0.822	0.215	.040	3	view →
LSCC	OS	Tertile	All	0.931	0.781	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RMDN1–CCRCC (DFS)

Open the CCRCC breakdown →